Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anthony H Barnett

Showing results (1-10 of 120) with videos related to

Pageof 12
Sort By:
Clinical Endocrinology|September 6, 2008
New treatments in type 2 diabetes: a focus on the incretin-based therapiesAnthony H Barnett
Primary Care Diabetes|August 8, 2008
The future of inhaled insulin and incretinmimetics in the management of diabetesAnthony H Barnett
Diabetic Medicine : a Journal of the British Diabetic Association|November 25, 2003
A review of basal insulinsAnthony H Barnett
Advances in Therapy|May 24, 2011
Linagliptin: a novel dipeptidyl peptidase 4 inhibitor with a unique place in therapyAnthony H Barnett
The Practitioner|February 21, 2002
Dyslipidaemia in diabetes--a GP guideAnthony H Barnett
Vascular Health and Risk Management|February 27, 2007
Insulin glargine in the treatment of type 1 and type 2 diabetesAnthony H Barnett
Current Medical Research and Opinion|April 8, 2010
Avoiding hypoglycaemia while achieving good glycaemic control in type 2 diabetes through optimal use of oral agent therapyAnthony H Barnett
Advances in Therapy|June 26, 2013
Complementing insulin therapy to achieve glycemic controlAnthony H Barnett
Diabetes, Obesity & Metabolism|April 26, 2008
Treatment intensification in patients with type 2 diabetesAnthony H Barnett
Diabetes & Vascular Disease Research|April 10, 2008
The importance of treating cardiometabolic risk factors in patients with type 2 diabetesAnthony H Barnett
Pageof 12

Showing results (1-10 of 120) with videos related to

Sort By:
Pageof 12
Clinical Endocrinology|September 6, 2008
New treatments in type 2 diabetes: a focus on the incretin-based therapiesAnthony H Barnett
Primary Care Diabetes|August 8, 2008
The future of inhaled insulin and incretinmimetics in the management of diabetesAnthony H Barnett
Diabetic Medicine : a Journal of the British Diabetic Association|November 25, 2003
A review of basal insulinsAnthony H Barnett
Advances in Therapy|May 24, 2011
Linagliptin: a novel dipeptidyl peptidase 4 inhibitor with a unique place in therapyAnthony H Barnett
The Practitioner|February 21, 2002
Dyslipidaemia in diabetes--a GP guideAnthony H Barnett
Vascular Health and Risk Management|February 27, 2007
Insulin glargine in the treatment of type 1 and type 2 diabetesAnthony H Barnett
Current Medical Research and Opinion|April 8, 2010
Avoiding hypoglycaemia while achieving good glycaemic control in type 2 diabetes through optimal use of oral agent therapyAnthony H Barnett
Advances in Therapy|June 26, 2013
Complementing insulin therapy to achieve glycemic controlAnthony H Barnett
Diabetes, Obesity & Metabolism|April 26, 2008
Treatment intensification in patients with type 2 diabetesAnthony H Barnett
Diabetes & Vascular Disease Research|April 10, 2008
The importance of treating cardiometabolic risk factors in patients with type 2 diabetesAnthony H Barnett
Pageof 12